Benzoylenurea

Benzoylenurea

SCHEMBL357451

O=c1nc(O)c2ccccc2[nH]1

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
KDM4E B2RXH2 6/20 0.58
HSD17B10 Q99714 3/20 0.58
HPGD P15428 2/20 0.58
TSHR P16473 1/20 0.58
ADORA3 P0DMS8 4/20 0.51
MAPT P10636 2/20 0.50
IDE P14735 1/20 0.50
MPI P34949 1/20 0.50
CACNA1B Q00975 1/20 0.50
APBA1 Q02410 1/20 0.50
APP P05067 2/20 0.49
LMNA P02545 2/20 0.48
GAA P10253 2/20 0.48
GLA P06280 1/20 0.48
HTT P42858 1/20 0.48
ATM Q13315 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
DAO P14920 1/20 0.46
DDO Q99489 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzoylenurea SCHEMBL29947820 1.00 ALDH1A1 (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL554709 0.76 KDM4E (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL6076792 0.76 KDM4E (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL30293081 0.76 ALDH1A1 (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL196018 0.76 KDM4E (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL6099088 0.76 KDM4E (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL4413903 0.76 KDM4E (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL530191 0.76 ALDH1A1 (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL3139711 0.76 KDM4E (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL29844822 0.76 KDM4E (0.58) ALDH1A1KDM4EHSD17B10HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966476-B1 Quinazolinone compounds UNIV NEWCASTLE VENTURES LTD (GB) 2002-09-04 EP claimed
US-6156739-A Quinazolinone compounds NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 2000-12-05 US claimed
EP-0966476-A1 QUINAZOLINONE COMPOUNDS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1999-12-29 EP claimed
WO-1998033802-A1 QUINAZOLINONE COMPOUNDS NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) 1998-08-06 WO claimed
EP-4634171-A1 PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE F. Hoffmann-La Roche AG (CH) 2025-10-22 EP disclosed
US-20250313551-A1 PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE HOFFMANN-LA ROCHE INC. (US) 2025-10-09 US disclosed
WO-2024126634-A1 PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE F. HOFFMANN-LA ROCHE AG (CH) 2024-06-20 WO disclosed
EP-3943494-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2022-01-26 EP disclosed
US-20210332047-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORP (US) 2021-10-28 US disclosed
EP-3153514-B1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORP (US) 2021-04-21 EP disclosed
US-10906907-B2 Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof ICOS CORPORATION (US) 2021-02-02 US disclosed
US-10336756-B2 (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta ICOS CORPORATION (US) 2019-07-02 US disclosed
EP-0107398-B1 ORTHO SUBSTITUTED DIHYDROXY-2(1H)QUINAZOLINONE-1-ALKANOIC ACIDS ORTHO PHARMA CORP (US) 1988-06-08 EP disclosed
US-4656267-A RENAL VASODILATORS, CARDIOVASCULAR AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1987-04-07 US disclosed
US-4631283-A RENAL VASODILATORS, CARDIOVASCULAR AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1986-12-23 US disclosed
US-4555571-A Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters ORTHO PHARMACEUTICAL CORPORATION (US) 1985-11-26 US disclosed
EP-0138491-A2 Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters ORTHO PHARMACEUTICAL CORPORATION (US) 1985-04-24 EP disclosed
US-4490374-A CARDIOVASCULAR AGENTS ORTHO PHARMACEUTICAL CORPORATION (US) 1984-12-25 US disclosed
EP-0107398-A1 Ortho substituted dihydroxy-2(1H)quinazolinone-1-alkanoic acids ORTHO PHARMACEUTICAL CORPORATION (US) 1984-05-02 EP disclosed
US-4258187-A REACTING 2-AMINO-BENZOPHENONE DERIVATIVES WITH A HYDROXYLAMINE SALT E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336756-B2 (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PI4KA ALDH1A1 3766/4885KDM4E 2553/4885HSD17B10 3452/4885
US-20210332047-A1 QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PI4KA ALDH1A1 4175/4885KDM4E 3421/4885HSD17B10 1773/4885
US-10906907-B2 Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof PIK3CD, PIK3CA, PIK3CB ALDH1A1 4185/4885KDM4E 973/4885HSD17B10 3120/4885
US-20250313551-A1 PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE NQO2, SDHA, NDUFS3 ALDH1A1 1347/4885KDM4E 619/4885HSD17B10 2947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.